[go: up one dir, main page]

MA53743A - METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS - Google Patents

METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS

Info

Publication number
MA53743A
MA53743A MA053743A MA53743A MA53743A MA 53743 A MA53743 A MA 53743A MA 053743 A MA053743 A MA 053743A MA 53743 A MA53743 A MA 53743A MA 53743 A MA53743 A MA 53743A
Authority
MA
Morocco
Prior art keywords
aging
compositions
methods
disorders related
treating disorders
Prior art date
Application number
MA053743A
Other languages
French (fr)
Inventor
Steven P Braithwaite
S Sakura Minami
Karoly Nikolich
Sanket V Rege
Arnaud E J Teichert
Original Assignee
Alkahest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkahest Inc filed Critical Alkahest Inc
Publication of MA53743A publication Critical patent/MA53743A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA053743A 2018-09-26 2019-09-25 METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS MA53743A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862737017P 2018-09-26 2018-09-26

Publications (1)

Publication Number Publication Date
MA53743A true MA53743A (en) 2022-01-05

Family

ID=69953286

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053743A MA53743A (en) 2018-09-26 2019-09-25 METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS

Country Status (16)

Country Link
EP (1) EP3856195A4 (en)
JP (2) JP7528065B2 (en)
KR (1) KR20210065950A (en)
CN (1) CN112789044A (en)
AU (1) AU2019346456A1 (en)
BR (1) BR112021004938A2 (en)
CA (1) CA3111433A1 (en)
CL (1) CL2021000724A1 (en)
CO (1) CO2021003713A2 (en)
EA (1) EA202190463A1 (en)
IL (1) IL281578A (en)
MA (1) MA53743A (en)
MX (1) MX2021002967A (en)
SG (1) SG11202102105VA (en)
TW (1) TW202027752A (en)
WO (1) WO2020069008A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113166085B (en) 2018-09-25 2024-04-09 安塔比奥公司 Indane derivatives for treating bacterial infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200538098A (en) * 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1996551A2 (en) * 2006-03-07 2008-12-03 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
US8278302B2 (en) * 2009-04-08 2012-10-02 Boehringer Ingelheim International Gmbh Substituted piperidines as CCR3 antagonists
PE20120810A1 (en) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc COMPOUNDS DERIVED FROM 5-CYANE-2- (PHENYLTHIUM) BENCENSULFONAMIDE AS ANTAGONISTS OF CCR3
US20160208011A1 (en) * 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
UA109290C2 (en) 2010-10-07 2015-08-10 Common Crystals and Salts of CCR3 Inhibitors
US20130261153A1 (en) * 2012-04-03 2013-10-03 Boehringer Ingelheim International Gmbh Use of ccr3-inhibitors
US10213421B2 (en) * 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
MX394341B (en) * 2017-04-05 2025-03-24 Alkahest Inc Methods and compositions for treating aging-associated impairments using ccr3-inhibitors
EP3606521B1 (en) * 2017-04-05 2023-04-19 Alkahest, Inc. Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors

Also Published As

Publication number Publication date
JP7528065B2 (en) 2024-08-05
IL281578A (en) 2021-05-31
JP2022502441A (en) 2022-01-11
BR112021004938A2 (en) 2021-06-01
EP3856195A1 (en) 2021-08-04
TW202027752A (en) 2020-08-01
CO2021003713A2 (en) 2021-04-08
SG11202102105VA (en) 2021-04-29
AU2019346456A1 (en) 2021-04-15
KR20210065950A (en) 2021-06-04
WO2020069008A1 (en) 2020-04-02
CN112789044A (en) 2021-05-11
EP3856195A4 (en) 2022-06-22
MX2021002967A (en) 2021-08-11
EA202190463A1 (en) 2021-06-29
CL2021000724A1 (en) 2021-10-15
CA3111433A1 (en) 2020-04-02
JP2024153742A (en) 2024-10-29

Similar Documents

Publication Publication Date Title
EP2352517A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF COMPLEMENT RELATED DISORDERS
EP3765094A4 (en) GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
EP3917539A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS
EP3793566A4 (en) COMPOSITIONS AND METHODS FOR REDUCING SPLICING DEFECTS AND TREATING RNA DOMINANCE DISORDERS
MA54609A (en) AZA-HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF CANCER
MA56050A (en) HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF CANCER
MA54608A (en) AZA-HETEROBICYCLIC MAT2A INHIBITORS AND METHODS OF USE FOR THE TREATMENT OF CANCER
MA54880A (en) COMPOSITIONS AND METHODS FOR TREATING NEUROCOGNITIVE DISORDERS
EP3490366A4 (en) METHODS AND COMPOSITIONS FOR THE EXPRESSION OF GENES IN PLANTS
EP3799602A4 (en) COMPOUNDS AND METHODS FOR REDUCING ATXN3 EXPRESSION
EP4096439A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISORDERS RELATED TO AGING
EP3368080A4 (en) TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF PXR AGONISTS AND THYROID HORMONES
EP3793562A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
MA53445A (en) METHODS AND COMPOSITIONS FOR THE MODIFICATION OF PLANTS
EP4045046A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF IRON-RELATED DISORDERS
MA53234A (en) MASP-2 INHIBITION COMPOSITIONS AND METHODS FOR TREATING VARIOUS THROMBOTIC DISORDERS AND DISEASES
EP3924478A4 (en) COMPOSITIONS AND METHODS FOR TREATING GLYCOGENOSIS TYPE 1A
EP3813793C0 (en) COMPOSITION FOR TREATING OCULAR HYPEREMIA AND METHOD FOR TREATING OCULAR HYPEREMIA USING SAME
EP3701048A4 (en) METHODS AND COMPOSITIONS FOR ASSESSING AND TREATING INTRAOCULAR DISEASES AND DISORDERS
EP2349320A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
EP2453743A4 (en) N-ACETYL CYSTEINE COMPOSITIONS AND METHODS FOR IMPROVING THE THERAPEUTIC EFFECTIVENESS OF ACETAMINOPHEN
EP3735457A4 (en) COMPOSITIONS AND METHODS FOR PRODUCING MEGACARYOCYTES
EP3969041A4 (en) COMPOSITIONS AND METHODS FOR TREATING T LYMPHOCYTE DEPLETION
EP3801577A4 (en) METHODS AND COMPOSITIONS INCLUDING TANKYRASE INHIBITORS FOR PRODUCING INSULIN-PRODUCING CELLS
EP3737367A4 (en) METHODS OF TREATING SOLID TUMORS USING CCR2 ANTAGONISTS